Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BLL006
MIFTS: 65

Bullous Pemphigoid

Categories: Immune diseases, Rare diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Bullous Pemphigoid

About this section

MalaCards integrated aliases for Bullous Pemphigoid:

Name: Bullous Pemphigoid 12 76 53 59 15 73
Senile Dermatitis Herpetiformis 53 73
Benign Pemphigus 53 73
Pemphigoid 53 37
Pemphigoid, Bullous 44
Pemphigoid Bullous 55
Old Age Pemphigus 53
Parapemphigus 53

Characteristics:

Orphanet epidemiological data:

59
bullous pemphigoid
Age of onset: All ages;

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Skin diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 33 34
Orphanet: 59  
Rare skin diseases


External Ids:

Disease Ontology 12 DOID:8506
ICD10 33 L12 L12.0 L12.9
ICD9CM 35 694.5
MeSH 44 D010391
SNOMED-CT 68 77090002 86142006
Orphanet 59 ORPHA703
MESH via Orphanet 45 D010391
UMLS via Orphanet 74 C0030805
ICD10 via Orphanet 34 L12.0
KEGG 37 H01650
Sources

Summaries for Bullous Pemphigoid

About this section
NIH Rare Diseases : 53 Bullous pemphigoid is a skin disorder characterized by large blisters. The blisters are usually located on the arms, legs, or middle of the body. In some people, the mouth or genitals are also affected. The blisters may break open and form ulcers or open sores. Bullous pemphigoid usually occurs in older persons and is rare in young people. Symptoms may come and go. In most patients, the condition goes away after several years. Bullous pemphigoid is an autoimmune disorder which occurs when the body's immune system attacks and destroys healthy body tissue by mistake. Treatment may include corticosteroids taken by mouth or applied to the skin. Medicines that suppress the immune system may also be prescribed. For some, antibiotics in the tetracycline family are useful.

MalaCards based summary : Bullous Pemphigoid, also known as senile dermatitis herpetiformis, is related to lichen planus pemphigoides and herpes gestationis. An important gene associated with Bullous Pemphigoid is COL17A1 (Collagen Type XVII Alpha 1 Chain), and among its related pathways/superpathways are ERK Signaling and Integrin Pathway. The drugs Prednisone and Clobetasol have been mentioned in the context of this disorder. Affiliated tissues include skin, neutrophil and t cells, and related phenotypes are diabetes mellitus and abnormal blistering of the skin

Disease Ontology : 12 An autoimmune disease of skin and connective tissue characterized by large blisters.

Wikipedia : 76 Bullous pemphigoid is an acute or chronic autoimmune skin disease, involving the formation of blisters,... more...

Sources

Related Diseases for Bullous Pemphigoid

About this section

Diseases related to Bullous Pemphigoid via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 372)
# Related Disease Score Top Affiliating Genes
1 lichen planus pemphigoides 32.8 COL17A1 DST ITGB4
2 herpes gestationis 31.1 COL17A1 DST RNASE3
3 epidermolysis bullosa acquisita 31.0 COL17A1 DST ITGB4 LAMA3
4 dermatitis herpetiformis 31.0 CCL11 CD79A HLA-DQB1
5 lichen planus 30.7 COL17A1 DSG3 DST
6 hypereosinophilic syndrome 30.5 CCL11 IL5 RNASE3
7 linear iga disease 30.5 CD79A COL17A1 DST ITGB4
8 lichen sclerosus 30.5 COL17A1 HLA-DQB1 HLA-DRB1
9 pemphigoid gestationis 30.4 CCL11 COL17A1 DST HLA-DRB1 IL5
10 conjunctivitis 30.3 CCL11 IL5 RNASE3
11 epidermolysis bullosa 30.3 COL17A1 DSP DST ITGA6 ITGB4 LAMA3
12 esophagitis 30.3 CCL11 DSG1 IL5
13 epidermolysis bullosa simplex 30.3 COL17A1 DST ITGB4 PLEC
14 herpetiform pemphigus 30.2 DSG1 DSG3 DST
15 pemphigus foliaceus 30.2 DSG1 DSG3 DST EVPL HLA-DRB1 PPL
16 cicatricial pemphigoid 30.2 CD79A COL17A1 DST ITGA6 ITGB4 LAMA3
17 pemphigus 30.2 CD79A COL17A1 DSG1 DSG3 DSP DST
18 gastroenteritis 30.1 CCL11 IL5 RNASE3
19 chronic eosinophilic pneumonia 30.1 CCL11 IL5 RNASE3
20 eosinophilic pneumonia 30.1 CCL11 IL5 RNASE3
21 pemphigus vulgaris 30.1 DSG1 DSG3 DSP DST EVPL HLA-DRB1
22 epidermolysis bullosa, junctional, non-herlitz type 30.0 COL17A1 DST ITGA6 ITGB4 LAMA3 LAMB3
23 junctional epidermolysis bullosa 29.9 COL17A1 DST ITGA6 ITGB4 LAMA3 LAMB3
24 autoimmune disease 29.8 CD79A COL17A1 DSG1 HLA-DQB1 HLA-DRB1 IL5
25 chronic conjunctivitis 29.7 CCL11 IL5 RNASE3
26 keratoconjunctivitis 29.7 CCL11 IL5 RNASE3
27 bronchiolitis 29.7 CCL11 IL5 RNASE3
28 ocular cicatricial pemphigoid 29.6 CD79A HLA-DQB1 HLA-DRB1 ITGA6 ITGB4 RNASE3
29 pemphigus vegetans 29.6 DSG1 PPL
30 atopic keratoconjunctivitis 29.4 IL5 RNASE3
31 paraneoplastic pemphigus 29.4 COL17A1 DSG1 DSG3 DSP DST EVPL
32 microscopic colitis 29.3 CD79A HLA-DQB1 HLA-DRB1
33 subcorneal pustular dermatosis 29.2 CD79A COL17A1 DSG1 DSG3 DST EVPL
34 cellulitis 29.0 COL17A1 DSG1 DSG3 DSP DST IL5
35 skin disease 28.3 CCL11 CD79A COL17A1 DSG1 DSG3 DSP
36 brunsting-perry syndrome 11.5
37 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 11.3
38 autoimmune disease, multisystem, infantile-onset, 2 11.3
39 recessive dystrophic epidermolysis bullosa-generalized other 11.3
40 pseudomembranous conjunctivitis 11.0
41 dermatitis 10.7
42 psoriasis 10.7
43 dermatitis herpetiformis, familial 10.7
44 pemphigus vulgaris, familial 10.6
45 melanoma 10.4
46 lupus erythematosus 10.4
47 scabies 10.4
48 psoriasis 2 10.3
49 psoriasis 7 10.3
50 psoriasis 11 10.3

Comorbidity relations with Bullous Pemphigoid via Phenotypic Disease Network (PDN):


Acute Cystitis Decubitus Ulcer
Deficiency Anemia Heart Disease
Pemphigus Protein-Energy Malnutrition
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Bullous Pemphigoid:



Diseases related to Bullous Pemphigoid
Sources

Symptoms & Phenotypes for Bullous Pemphigoid

About this section

Human phenotypes related to Bullous Pemphigoid:

59 32 (show all 10)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 diabetes mellitus 59 32 hallmark (90%) Very frequent (99-80%) HP:0000819
2 abnormal blistering of the skin 59 32 hallmark (90%) Very frequent (99-80%) HP:0008066
3 weight loss 59 32 hallmark (90%) Very frequent (99-80%) HP:0001824
4 autoimmunity 59 32 hallmark (90%) Very frequent (99-80%) HP:0002960
5 recurrent infections 59 32 hallmark (90%) Very frequent (99-80%) HP:0002719
6 erythema 59 32 hallmark (90%) Very frequent (99-80%) HP:0010783
7 macule 59 32 hallmark (90%) Very frequent (99-80%) HP:0012733
8 eczema 59 32 hallmark (90%) Very frequent (99-80%) HP:0000964
9 urticaria 59 32 hallmark (90%) Very frequent (99-80%) HP:0001025
10 psoriasiform dermatitis 59 32 frequent (33%) Frequent (79-30%) HP:0003765

GenomeRNAi Phenotypes related to Bullous Pemphigoid according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 10.03 CD79A HLA-DQB1
2 Decreased viability GR00381-A-3 10.03 CD79A HLA-DQB1
3 Decreased viability GR00402-S-2 10.03 CCL11 CD79A COL17A1 DSG1 DSG3 DSP
4 no effect GR00402-S-1 9.62 CCL11 CD79A COL17A1 DSG1 DSG3 DSP

MGI Mouse Phenotypes related to Bullous Pemphigoid:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10 DSG1 DSG3 DSP HLA-DQB1 IL5 ITGA6
2 digestive/alimentary MP:0005381 9.97 DSG3 DSP HLA-DQB1 IL5 ITGA6 ITGB4
3 craniofacial MP:0005382 9.91 DSG3 DSP ITGA6 ITGB4 LAMA3 LAMB3
4 immune system MP:0005387 9.9 CCL11 CD79A DSG3 HLA-DQB1 IL5 ITGA6
5 integument MP:0010771 9.65 DSG1 DSG3 DSP EVPL ITGA6 ITGB4
6 respiratory system MP:0005388 9.28 CCL11 DSG3 HLA-DQB1 IL5 ITGA6 ITGB4
Sources

Drugs & Therapeutics for Bullous Pemphigoid

About this section

Drugs for Bullous Pemphigoid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 91)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Clobetasol Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2 25122-46-7, 25122-41-2 5311051 32798
3
Omalizumab Approved, Investigational Phase 4 242138-07-4
4 Antineoplastic Agents, Hormonal Phase 4
5 Hormone Antagonists Phase 4,Phase 3,Phase 2
6 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
7 Hormones Phase 4,Phase 3,Phase 2
8 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
9 glucocorticoids Phase 4,Phase 3,Phase 2
10 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
11 Immunoglobulin E Phase 4
12 Anti-Allergic Agents Phase 4
13 Respiratory System Agents Phase 4
14 Anti-Asthmatic Agents Phase 4
15 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
16
leucovorin Approved Phase 3 58-05-9 6006 143
17
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
18
rituximab Approved Phase 3,Phase 1,Phase 2 174722-31-7 10201696
19
Mycophenolic acid Approved Phase 3,Phase 2 24280-93-1 446541
20
Cyclophosphamide Approved, Investigational Phase 3 6055-19-2, 50-18-0 2907
21
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 59-30-3 6037
22 Folate Phase 3,Phase 1,Phase 2
23 Vitamin B9 Phase 3,Phase 1,Phase 2
24 Immunosuppressive Agents Phase 3,Phase 2
25 Vitamin B Complex Phase 3,Phase 1,Phase 2
26 Immunologic Factors Phase 3,Phase 2,Phase 1
27 Dermatologic Agents Phase 3,Phase 1,Phase 2,Not Applicable
28 Antimetabolites, Antineoplastic Phase 3,Phase 2
29 Antirheumatic Agents Phase 3,Phase 2,Phase 1
30 Folic Acid Antagonists Phase 3
31 Antimetabolites Phase 3,Phase 2,Phase 1
32 Nucleic Acid Synthesis Inhibitors Phase 3
33 Anti-Infective Agents Phase 3,Phase 2
34 Anti-Bacterial Agents Phase 3,Phase 2
35 gamma-Globulins Phase 3,Phase 2,Phase 1
36 Immunoglobulins, Intravenous Phase 3,Phase 2,Phase 1
37 Rho(D) Immune Globulin Phase 3,Phase 2,Phase 1
38 Antitubercular Agents Phase 3,Phase 2
39 Antibiotics, Antitubercular Phase 3,Phase 2
40 Antineoplastic Agents, Alkylating Phase 3
41 Alkylating Agents Phase 3
42
Leflunomide Approved, Investigational Phase 2 75706-12-6 3899
43
Azathioprine Approved Phase 2 446-86-6 2265
44
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
45
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
46
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
47
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
48 Ixekizumab Approved, Investigational Phase 2 1143503-69-8
49
Infliximab Approved Phase 1, Phase 2 170277-31-3
50
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 1, Phase 2 83-88-5 493570

Interventional clinical trials:

(show all 48)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Omalizumab in Bullous Pemphigoid Completed NCT00472030 Phase 4 Omalizumab;prednisone
2 Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid Recruiting NCT02360202 Phase 4 Clobetasol Propionate cream treatment
3 Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid Unknown status NCT02313870 Phase 3 clobetasol propionate + Methotrexate;clobetasol propionate alone
4 Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid Completed NCT00525616 Phase 3 Mabthera
5 Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids Completed NCT01408550 Phase 3 NPB-01;Placebo
6 Pharmacokinetics Study of Mycophenolic Acid in Patients With an Autoimmune Bullous Dermatose, Pemphigus or Cicatricial Pemphigoid. Recruiting NCT02993133 Phase 3 Cellcept® in autoimmune bullous dermatoses
7 Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid Not yet recruiting NCT03295383 Phase 3 Rituximab 1g IV;Cyclophosphamide 50Mg Oral Tablet;Placebo of Rituximab;Placebo Oral Tablet
8 Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid Unknown status NCT00802243 Phase 2 leflunomide
9 Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids. Completed NCT00809822 Phase 2 NPB-01;Placebo
10 Azathioprine or Mycophenolate Mofetil for Bullous Pemphigoid Completed NCT00431119 Phase 2 Azathioprine or Mycophenolate mofetil
11 Rituximab in the Treatment of Patients With Bullous Pemphigoid Completed NCT00286325 Phase 1, Phase 2 Rituximab
12 Anti-IL-5 Therapy in Bullous Pemphigoid (BP) Completed NCT01705795 Phase 2 Mepolizumab (a-IL-5 antibody);Placebo
13 Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid Completed NCT02226146 Phase 2
14 Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid Completed NCT00584935 Phase 1, Phase 2 Rituximab
15 Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis Completed NCT01582880 Phase 1, Phase 2 Riboflavin
16 Ixekizumab in the Treatment of Bullous Pemphigoid Recruiting NCT03099538 Phase 2 Ixekizumab
17 A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid Recruiting NCT03286582 Phase 2 AC-203 1% Topical Ointment;Clobetasol 0.05% Topical Ointment
18 Limbal Epithelial Stem Cell Transplantation: a Phase II Multicenter Trial Recruiting NCT02318485 Phase 2
19 Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment Terminated NCT01688882 Phase 2 QGE031;Placebo
20 Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid Terminated NCT01571895 Phase 2 DF2156A
21 Topical Infliximab in Autoimmune Eyes With Keratoprosthesis Withdrawn NCT02126020 Phase 1, Phase 2 topical infliximab
22 The Improvement of Limbal Epithelial Culture Technique by Using Collagenase to Isolate Limbal Stem Cells Unknown status NCT02202642 Phase 1
23 Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies Completed NCT00691210 Phase 1 Vorinostat;Niacinamide;Etoposide
24 Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders Recruiting NCT02502903 Phase 1 BIV009
25 Topical Infliximab for Sterile Corneal Melt Recruiting NCT02987686 Phase 1 Topical Infliximab
26 Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions Withdrawn NCT02042027 Phase 1 Gamunex-C
27 Genetic Susceptibility and Influence of the Microbiomae in Bullous Pemphigoid Unknown status NCT02874079 Not Applicable
28 Observational Study Assessing Outcomes, Treatment Patterns and Related Costs in Patients in Bullous Pemphigoid Unknown status NCT02837965 treatment with topical superpotent corticosteroid therapy;treatment with systemic therapy (methotrexate);treatment systemic therapy (prednisone);treatment with systemic therapy (prednisone);treatment with systemic therapy (doxycycline)
29 Explore the Mechanisms of Pruritus in Bullous Pemphigoid Patients During Remission Unknown status NCT01265082
30 Wound Dressings for Pemphigus and Pemphigoid Unknown status NCT02365675 Not Applicable
31 Serum FFA Desaturase Activity Index in Patients on High Dose Corticosteroids Unknown status NCT02872584 Prednisone
32 Interest of Dosage of Anti-PB230, Anti-PB180 and Cytokines for Monitoring of Patients Suffering From Bullous Pemphigoid Completed NCT02883894
33 Clinical Characteristics of Pruritus and Evaluation of Quality of Life in Patients With Bullous Pemphigoid Completed NCT03272958
34 Impact of Neurological Diseases on the Prognosis of Bullous Pemphigoid: A Retrospective Study of 178 Patients Completed NCT03320798
35 Pruritus and Pemphigoid in Nursing Home Patients Completed NCT02823067
36 Comparison of Two Therapeutic Strategies of Dermoval in Treatment of Bullous Pemphigus Completed NCT00213421 Dermoval
37 Register of Autoimmune Bullous Dermatoses Completed NCT02899923
38 Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study Completed NCT00116090
39 A Study of the Association of Sleep Dysfunction and Burning Mouth Syndrome Completed NCT00862576
40 Immune Responses to Antigens in Non-infectious Eye Inflammatory Diseases Completed NCT00357071
41 Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid? Recruiting NCT03636763 data report
42 Autoimmune Blistering Diseases Study Recruiting NCT02753777
43 Prevalence of Cutaneous Autoimmune Phenomena in HIV Infected Patients Recruiting NCT03129308
44 Identification of Vulnerability Factors in the Course of Pemphigus Patients Recruiting NCT02237313 Not Applicable
45 Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation Available NCT02149732
46 Trichoscopy in Diagnosis of Immunobollous Diseases Not yet recruiting NCT03478072
47 Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid Terminated NCT01559155
48 Implantable Intraocular Pressure Sensor for Glaucoma Monitoring in Patients With Boston Keratoprosthesis Type 1 Withdrawn NCT03421548 Not Applicable

Search NIH Clinical Center for Bullous Pemphigoid

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: pemphigoid, bullous

Sources

Genetic Tests for Bullous Pemphigoid

About this section
Sources

Anatomical Context for Bullous Pemphigoid

About this section

MalaCards organs/tissues related to Bullous Pemphigoid:

41
Skin, Neutrophil, T Cells, Breast, B Cells, Testes, Lung
Sources

Publications for Bullous Pemphigoid

About this section

Articles related to Bullous Pemphigoid:

(show top 50) (show all 1391)
# Title Authors Year
1
Bullous erythroderma: novel association of pityriasis rubra pilaris with bullous pemphigoid. ( 30129048 )
2019
2
Cutaneous Mucormycosis Following a Bullous Pemphigoid Flare in a Chronic Lymphocytic Leukemia Patient on Ibrutinib. ( 29760835 )
2018
3
HLA-C*17, DQB1*03:01, DQA1*01:03 and DQA1*05:05 Alleles Associated to Bullous Pemphigoid in Brazilian Population. ( 29386826 )
2018
4
Mortality and Comorbidity Profiles of Patients with Bullous Pemphigoid in Korea. ( 29386827 )
2018
5
A case of bullous pemphigoid with IgG antibodies against LAD-1, but not BP180 NC16a domain or BP230. ( 29378676 )
2018
6
Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in a patient with acquired reactive perforating collagenosis. ( 29446164 )
2018
7
Regulatory T-cell deficiency leads to pathogenic bullous pemphigoid antigen 230 autoantibody and autoimmune bullous disease. ( 29704595 )
2018
8
Circulating anti-bullous pemphigoid 180 autoantibody can be detected in a wide clinical spectrum: A cross-sectional study. ( 29906544 )
2018
9
Localized bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor treatment. ( 29400293 )
2018
10
Bullous Pemphigoid Associated with Adalimumab Therapy in a Patient with Ulcerative Colitis. ( 29928204 )
2018
11
Modes of Action of Intravenous Immunoglobulin in Bullous Pemphigoid. ( 29793619 )
2018
12
Reflectance confocal microscopy and optical coherence tomography for the diagnosis of bullous pemphigoid and pemphigus and surrounding sub-clinical lesions. ( 29341355 )
2018
13
Detection of I+-defensin in blister fluids as potential biomarkers for bullous pemphigoid patients by matrix-assisted laser desorption ionization/time-of-flight mass spectrometry. ( 29407691 )
2018
14
Bullous Pemphigoid Triggered by Thermal Burn Under Medication With a Dipeptidyl Peptidase-IV Inhibitor: A Case Report and Review of the Literature. ( 29706950 )
2018
15
Light Chain Deposition Disease with Bullous Skin Lesions Mimicking Atypical Bullous Pemphigoid. ( 29135016 )
2018
16
Intravenous immunoglobulin reduces pathogenic autoantibodies, serum IL-6 levels and disease severity in experimental bullous pemphigoid models. ( 29391250 )
2018
17
A case of acquired haemophilia A in a patient with bullous pemphigoid and review of the Japanese literature. ( 29952290 )
2018
18
Localized pretibial bullous pemphigoid arising in a patient on pembrolizumab for metastatic melanoma. ( 29389067 )
2018
19
Mortality in Patients with Bullous Pemphigoid: A Retrospective Cohort Study, Systematic Review and Meta-analysis. ( 29963683 )
2018
20
Livedoid vasculopathy in a patient with bullous pemphigoid and primary SjAPgren's syndrome. ( 29526676 )
2018
21
Mortality in bullous pemphigoid: A systematic review and meta-analysis of standardized mortality ratios. ( 29905389 )
2018
22
Vildagliptin significantly increases the risk of bullous pemphigoid: A Finnish nationwide registry study. ( 29427585 )
2018
23
Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: a Finnish nationwide case control study. ( 29803903 )
2018
24
Unilateral, localized bullous pemphigoid in a patient with chronic venous stasis. ( 29387773 )
2018
25
Bullous Pemphigoid in an Infant: A Case Report. ( 29929566 )
2018
26
TNF-I+ -308G/A gene polymorphism in bullous pemphigoid and alopecia areata. ( 29843231 )
2018
27
Amantadine-Associated Bullous Pemphigoid. ( 29912791 )
2018
28
Localized genital bullous pemphigoid. ( 29756688 )
2018
29
Case of bullous pemphigoid associated with teneligliptin accompanied by severe mucous membrane involvement. ( 29380425 )
2018
30
Clarithromycin as a steroid sparing agent for the management of infantile bullous pemphigoid. ( 29374651 )
2018
31
Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: a retrospective study of 168 pemphigoid and 9,304 diabetes mellitus cases. ( 29920976 )
2018
32
BPDAI and ABSIS correlate with serum anti-BP180 NC16A IgG but not with anti-BP230 IgG in patients with bullous pemphigoid. ( 29423547 )
2018
33
Hemorrhagic vesiculobullous eruption on the palms and the soles as presentation of dyshidrosiform bullous pemphigoid. ( 29387751 )
2018
34
Bullous pemphigoid complicated by necrotising fasciitis successfully treated with systemic corticosteroids and antibiotics in combination with i.v. immunoglobulin. ( 29797437 )
2018
35
Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid. ( 29411416 )
2018
36
Bulla formation at the tuberculin skin test site in a patient with bullous pemphigoid: Koebnerization or severe delayed-type hypersensitivity? ( 29376506 )
2018
37
High Index Values of Enzyme-Linked Immunosorbent Assay for BP180 at Baseline Predict Relapse in Patients With Bullous Pemphigoid. ( 29868591 )
2018
38
A Case of Bullous Pemphigoid: A Prevalent and Potentially Fatal Condition. ( 29946501 )
2018
39
Kaposi's sarcoma associated with localized bullous pemphigoid: two conflicting diseases. ( 29767490 )
2018
40
Safety gains don't translate into reduced costs or increased QALYs for doxycycline compared with prednisolone for patients with bullous pemphigoid. ( 29441558 )
2018
41
Association between bullous pemphigoid and psoriasis: Systematic review and meta-analysis of case-control studies. ( 30141189 )
2018
42
Bullous pemphigoid and neurological disorders among a Jewish population. ( 30142744 )
2018
43
Early-onset neutropenia after rituximab therapy for bullous pemphigoid. ( 30151931 )
2018
44
Lisinopril-associated bullous pemphigoid in an elderly woman: a case report of a rare adverse drug reaction. ( 30155951 )
2018
45
The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations. ( 30177969 )
2018
46
Adjuvant treatment of severe/refractory bullous pemphigoid with protein A immunoadsorption. ( 30179319 )
2018
47
A new clinical variant of acquired reactive perforating dermatosis-like bullous pemphigoid. ( 30188568 )
2018
48
Minocycline decreases Th2 chemokines from M2 macrophages: Possible mechanisms for the suppression of bullous pemphigoid by traditional bullous disease drugs. ( 30192415 )
2018
49
Bullous Pemphigoid Induced by Metamizole in a Pediatric Patient. ( 30210165 )
2018
50
A case of Bullous Pemphigoid Associated with Lichen Sclerosus et Atrophicus. ( 30210168 )
2018
Sources

Variations for Bullous Pemphigoid

About this section
Sources

Expression for Bullous Pemphigoid

About this section
Search GEO for disease gene expression data for Bullous Pemphigoid.
Sources

Pathways for Bullous Pemphigoid

About this section

Pathways related to Bullous Pemphigoid according to GeneCards Suite gene sharing:

(show all 28)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 64
Show member pathways
 13.77 CCL11 COL17A1 DSP IL5 ITGA6 ITGB4
2
Integrin Pathway 64
Show member pathways
 13.31 CCL11 COL17A1 ITGA6 ITGB4 LAMA3 LAMB3
3
Phospholipase-C Pathway 64
Show member pathways
 12.96 CD79A COL17A1 ITGA6 ITGB4 LAMA3 LAMB3
4
Focal Adhesion 1 37
Show member pathways
 12.8 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
5
Allograft rejection 1 37
Show member pathways
 12.79 CCL11 HLA-DQB1 HLA-DRB1 IL5 RNASE3 TNFSF13B
6
Pathways in cancer 37
12.74 IL5 ITGA6 LAMA3 LAMB3 LAMC2
7
Beta-Adrenergic Signaling 64
Show member pathways
 12.71 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
8
Collagen chain trimerization 66
Show member pathways
 12.65 COL17A1 DST ITGA6 ITGB4 LAMA3 LAMB3
9
Keratinization 66
Show member pathways
 12.41 DSG1 DSG3 DSP EVPL PPL
10
Degradation of the extracellular matrix 66
Show member pathways
 12.41 COL17A1 DST ITGA6 ITGB4 LAMA3 LAMB3
11
MET promotes cell motility 66
Show member pathways
 12.22 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
12
Cell junction organization 66
Show member pathways
 12.18 COL17A1 DST ITGA6 ITGB4 LAMA3 LAMB3
13
Toxoplasmosis 37
Show member pathways
 12.12 HLA-DQB1 HLA-DRB1 ITGA6 LAMA3 LAMB3 LAMC2
14
G-protein signaling Regulation of p38 and JNK signaling mediated by G-proteins 22
Show member pathways
 12.1 CCL11 COL17A1 ITGA6 ITGB4 LAMA3 LAMB3
15
ECM-receptor interaction 37
Show member pathways
 12.01 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
16
Adhesion 4
11.96 DSP ITGA6 ITGB4 PLEC
17
Apoptotic cleavage of cellular proteins 66
Show member pathways
 11.9 DSG1 DSG3 DSP PLEC
18
Cytoskeleton remodeling Neurofilaments 22
Show member pathways
 11.84 DSP DST EVPL PLEC PPL
19
Hematopoietic cell lineage 37
11.8 HLA-DQB1 HLA-DRB1 IL5 ITGA6
20
Amoebiasis 37
11.79 LAMA3 LAMB3 LAMC2
21
Small cell lung cancer 37
11.76 ITGA6 LAMA3 LAMB3 LAMC2
22
Rheumatoid arthritis 37
11.75 HLA-DQB1 HLA-DRB1 TNFSF13B
23
Lung fibrosis 1
11.57 CCL11 DSP IL5
24
Cell adhesion_ECM remodeling 22
11.55 LAMA3 LAMB3 LAMC2
25
Staphylococcus aureus infection 37
11.51 DSG1 HLA-DQB1 HLA-DRB1
26
Non-integrin membrane-ECM interactions 66
Show member pathways
 11.48 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
27
a6b1 and a6b4 Integrin signaling 1
11.22 COL17A1 ITGA6 ITGB4
28
G-protein signaling_Rap2B regulation pathway 22
10.18 CCL11 COL17A1 IL5 ITGA6 ITGB4 LAMA3
Sources

GO Terms for Bullous Pemphigoid

About this section

Cellular components related to Bullous Pemphigoid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell junction GO:0030054 9.97 COL17A1 DSG1 DSG3 DSP DST EVPL
2 intermediate filament GO:0005882 9.77 DSP DST EVPL PLEC PPL
3 cornified envelope GO:0001533 9.65 DSG1 DSG3 DSP EVPL PPL
4 basement membrane GO:0005604 9.63 COL17A1 DST ITGA6 LAMA3 LAMB3 LAMC2
5 MHC class II protein complex GO:0042613 9.48 HLA-DQB1 HLA-DRB1
6 laminin-5 complex GO:0005610 9.4 LAMA3 LAMB3
7 desmosome GO:0030057 9.35 DSG1 DSG3 DSP EVPL PPL
8 hemidesmosome GO:0030056 9.02 COL17A1 DST ITGA6 ITGB4 PLEC
9 membrane GO:0016020 10.33 CD79A COL17A1 DSG1 DSG3 DSP DST
10 plasma membrane GO:0005886 10.25 CD79A COL17A1 DSG1 DSG3 DSP DST

Biological processes related to Bullous Pemphigoid according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.93 CCL11 HLA-DQB1 HLA-DRB1 IL5 TNFSF13B
2 cell adhesion GO:0007155 9.91 CCL11 DSG1 DSG3 DST ITGA6 ITGB4
3 keratinization GO:0031424 9.83 DSG1 DSG3 DSP EVPL PPL
4 cornification GO:0070268 9.8 DSG1 DSG3 DSP EVPL PPL
5 extracellular matrix organization GO:0030198 9.8 COL17A1 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
6 wound healing GO:0042060 9.77 DSP DST EVPL PLEC PPL
7 cell-matrix adhesion GO:0007160 9.73 COL17A1 ITGA6 ITGB4
8 integrin-mediated signaling pathway GO:0007229 9.72 DST ITGA6 ITGB4
9 skin development GO:0043588 9.65 DSP ITGA6 ITGB4
10 epidermis development GO:0008544 9.63 COL17A1 DSP EVPL LAMA3 LAMB3 LAMC2
11 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.57 HLA-DQB1 HLA-DRB1
12 amelogenesis GO:0097186 9.52 ITGA6 ITGB4
13 nail development GO:0035878 9.51 ITGA6 ITGB4
14 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.49 HLA-DQB1 HLA-DRB1
15 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.46 HLA-DQB1 HLA-DRB1
16 intermediate filament cytoskeleton organization GO:0045104 9.35 DSP DST EVPL PLEC PPL
17 hemidesmosome assembly GO:0031581 9.23 COL17A1 DST ITGA6 ITGB4 LAMA3 LAMB3

Molecular functions related to Bullous Pemphigoid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cadherin binding GO:0045296 9.67 EVPL ITGA6 PLEC PPL
2 structural constituent of cytoskeleton GO:0005200 9.5 DSP PLEC PPL
3 insulin-like growth factor I binding GO:0031994 9.26 ITGA6 ITGB4
4 structural molecule activity GO:0005198 9.17 DSP DST EVPL LAMA3 LAMB3 PLEC
5 MHC class II receptor activity GO:0032395 9.16 HLA-DQB1 HLA-DRB1
6 neuregulin binding GO:0038132 8.96 ITGA6 ITGB4
Sources

Sources for Bullous Pemphigoid

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....